title: Response to the Letter by Kalra S. et al.
authors.forename: C K
authors.initials: CK
authors.lastname: Kramer
authors.forename: B
authors.initials: B
authors.lastname: Zinman
authors.forename: R
authors.initials: R
authors.lastname: Retnakaran
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D005260:Female; D005934:Glucagon / Q000097:blood*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069450:Liraglutide / Q000627:therapeutic use*; D008297:Male
chemical_list: D007004:Hypoglycemic Agents; D000069450:Liraglutide; D005934:Glucagon